Inclusion criteria required patients with sepsis and abnormal biomarkers indicating glycocalyx injury, as determined by elevated glycocalyx biomarkers (Syndecan-1 and endocan) and clinical outcome descriptions. This evidence concerns the gene SDC1 and Sepsis.